JP2018503373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503373A5 JP2018503373A5 JP2017534648A JP2017534648A JP2018503373A5 JP 2018503373 A5 JP2018503373 A5 JP 2018503373A5 JP 2017534648 A JP2017534648 A JP 2017534648A JP 2017534648 A JP2017534648 A JP 2017534648A JP 2018503373 A5 JP2018503373 A5 JP 2018503373A5
- Authority
- JP
- Japan
- Prior art keywords
- expression level
- determined
- cancer
- correlates
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021031306A JP7325463B2 (ja) | 2014-12-30 | 2021-03-01 | がんの予後診断及び治療のための方法及び組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098055P | 2014-12-30 | 2014-12-30 | |
| US62/098,055 | 2014-12-30 | ||
| PCT/US2015/067878 WO2016109546A2 (en) | 2014-12-30 | 2015-12-29 | Methods and compositions for prognosis and treatment of cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021031306A Division JP7325463B2 (ja) | 2014-12-30 | 2021-03-01 | がんの予後診断及び治療のための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018503373A JP2018503373A (ja) | 2018-02-08 |
| JP2018503373A5 true JP2018503373A5 (enExample) | 2019-01-31 |
Family
ID=55315702
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534648A Pending JP2018503373A (ja) | 2014-12-30 | 2015-12-29 | がんの予後診断及び治療のための方法及び組成物 |
| JP2021031306A Active JP7325463B2 (ja) | 2014-12-30 | 2021-03-01 | がんの予後診断及び治療のための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021031306A Active JP7325463B2 (ja) | 2014-12-30 | 2021-03-01 | がんの予後診断及び治療のための方法及び組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11236394B2 (enExample) |
| EP (1) | EP3240908A2 (enExample) |
| JP (2) | JP2018503373A (enExample) |
| CN (1) | CN107208138A (enExample) |
| WO (1) | WO2016109546A2 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| US12241053B2 (en) | 2015-10-09 | 2025-03-04 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| KR20180097615A (ko) | 2016-01-08 | 2018-08-31 | 에프. 호프만-라 로슈 아게 | Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법 |
| WO2018029124A1 (en) * | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
| JP7235508B2 (ja) * | 2016-11-24 | 2023-03-08 | 第一三共株式会社 | Ｐｄ－１免疫チェックポイント阻害剤による治療に対するがんの感受性を予測する方法 |
| MX2019006072A (es) | 2016-11-30 | 2019-08-14 | Oncomed Pharm Inc | Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit). |
| EP3333268A1 (en) * | 2016-12-09 | 2018-06-13 | Institut Paoli Calmettes | Biomarker panel for prognosis of bladder cancer |
| WO2018122249A1 (en) * | 2016-12-28 | 2018-07-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer |
| JP7206203B2 (ja) * | 2017-02-07 | 2023-01-17 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | がんの重症度を評価するためのｔｉｍ－３ |
| CN106950371B (zh) * | 2017-02-17 | 2019-03-08 | 张灏 | Pd-l1、cdk5和ctla4中的至少一种在制备肿瘤诊断试剂盒中的用途 |
| TW201837467A (zh) | 2017-03-01 | 2018-10-16 | 美商建南德克公司 | 用於癌症之診斷及治療方法 |
| GB202209539D0 (en) | 2017-06-13 | 2022-08-10 | Bostongene Corp | Systems and methods for identifying cancer treatments from normalized biomarker scores |
| CN111164103A (zh) * | 2017-06-14 | 2020-05-15 | 西奈山伊坎医学院 | 检测和治疗对免疫疗法应答的肝细胞癌类别的方法 |
| KR102348291B1 (ko) * | 2017-06-14 | 2022-01-07 | 연세대학교 산학협력단 | 암 환자의 치료 반응성을 예측하는 방법 |
| CA3069828A1 (en) * | 2017-07-14 | 2019-01-17 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
| WO2019117132A1 (ja) * | 2017-12-12 | 2019-06-20 | 地方独立行政法人神奈川県立病院機構 | がん免疫療法の予後予測のためのバイオマーカー |
| JP2021524744A (ja) * | 2018-05-21 | 2021-09-16 | ナノストリング テクノロジーズ，インコーポレイティド | 分子遺伝子シグネチャーとその使用方法 |
| CN108823309B (zh) * | 2018-06-11 | 2021-11-30 | 北京大学人民医院 | 检测kiaa0125基因表达水平的物质在辅助鉴定急性淋巴细胞白血病中的应用 |
| GB201810190D0 (en) * | 2018-06-21 | 2018-08-08 | Cancer Research Tech Ltd | Prognostic and treatment response predictive method |
| EP3833323A4 (en) * | 2018-08-08 | 2022-08-10 | Cedars-Sinai Medical Center | Compositions and methods for treating cancer and autoimmune diseases |
| KR102084196B1 (ko) * | 2018-08-29 | 2020-03-03 | 연세대학교 산학협력단 | 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| AU2019337603B2 (en) * | 2018-09-13 | 2026-03-05 | Nkarta, Inc. | Natural killer cell compositions and immunotherapy methods for treating tumors |
| CA3120563A1 (en) | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| EP4198057A1 (en) * | 2018-12-05 | 2023-06-21 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for cancer immunotherapy |
| CN109880894A (zh) * | 2019-03-05 | 2019-06-14 | 杭州西合森医学检验实验室有限公司 | 基于RNAseq的肿瘤免疫微环境预测模型的构建方法 |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| EP3947737A2 (en) * | 2019-04-02 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| WO2020207771A1 (en) * | 2019-04-10 | 2020-10-15 | Universität Zürich | A method for determining the likelihood of a patient being responsive to cancer immunotherapy |
| US20220363760A1 (en) * | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| EP3976040A1 (en) * | 2019-06-01 | 2022-04-06 | Ares Trading S.A. | Pd-1 axis binding antagonist to treat cancer with genetic mutations in specific genes |
| KR102042710B1 (ko) * | 2019-07-02 | 2019-11-08 | 의료법인 성광의료재단 | 면역체크 포인트와 관련된, 난소암 진단용 바이오마커 |
| CN110804642B (zh) * | 2019-09-10 | 2022-06-21 | 清华大学 | Gpr174免疫学功能及其用途 |
| JP2023504444A (ja) * | 2019-11-29 | 2023-02-03 | スンクワン メディカル ファウンデーション | 免疫治療剤に係わる治療反応性予測用バイオマーカー |
| US20210181200A1 (en) * | 2019-12-17 | 2021-06-17 | Women's College Hospital | Ovarian cancer biomarker and methods of using same |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| CN111500733B (zh) * | 2020-05-27 | 2022-03-08 | 中国人民解放军军事科学院军事医学研究院 | 外周血单核细胞中用于非小细胞肺癌早期诊断的分子标记物 |
| KR20230024368A (ko) | 2020-06-18 | 2023-02-20 | 제넨테크, 인크. | 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료 |
| KR102647295B1 (ko) * | 2020-09-03 | 2024-03-14 | 한국과학기술연구원 | 암 면역 치료의 효능 예측을 위한 바이오마커 및 이의 용도 |
| WO2022053065A1 (zh) * | 2020-09-14 | 2022-03-17 | 信达生物制药(苏州)有限公司 | 用于预测或评估肺癌患者的生物标志物、检测方法及应用 |
| WO2022109607A2 (en) * | 2020-11-19 | 2022-05-27 | Tempus Labs, Inc. | Determination of cytotoxic gene signature and associated systems and methods for response prediction and treatment |
| CN112530581B (zh) * | 2020-12-03 | 2023-11-21 | 安徽医科大学第一附属医院 | 一种前列腺癌患者的免疫分子分类系统及其应用 |
| EP4026918A1 (en) * | 2021-01-12 | 2022-07-13 | Koninklijke Philips N.V. | Prediction of an outcome of a colorectal cancer subject |
| CN112831562A (zh) * | 2021-01-25 | 2021-05-25 | 浙江科技学院 | 一种用于预测肝癌患者切除术后复发风险的生物标志物组合、试剂盒 |
| IL306090A (en) * | 2021-03-25 | 2023-11-01 | Oncxerna Therapeutics Inc | Targeted cancer treatments |
| WO2022211620A1 (en) * | 2021-04-01 | 2022-10-06 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Cd4/il-2 biomarker. |
| WO2023285521A1 (en) | 2021-07-15 | 2023-01-19 | Vib Vzw | Biomarkers predicting response of breast cancer to immunotherapy |
| JP7480754B2 (ja) | 2021-07-19 | 2024-05-10 | トヨタ自動車株式会社 | 蓄電装置 |
| WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| US20260049359A1 (en) * | 2022-05-19 | 2026-02-19 | Agendia N.V. | Prediction of response to immune therapy in breast cancer patients |
| KR20250022049A (ko) | 2022-06-07 | 2025-02-14 | 제넨테크, 인크. | 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법 |
| KR20240051492A (ko) * | 2022-10-13 | 2024-04-22 | 주식회사 네오셀라 | 대식세포 분화 및 분포에 따른 면역세포 치료제의 치료 반응성 예측 방법 |
| CN120826478A (zh) | 2023-03-06 | 2025-10-21 | 基因泰克公司 | 用于非小细胞肺癌的预后和治疗方法 |
| WO2024225488A1 (ja) * | 2023-04-27 | 2024-10-31 | 株式会社リプロセル | 抗ｐｄ－１抗体療法に応答性である候補がん患者を同定する方法 |
| WO2024234348A1 (en) * | 2023-05-17 | 2024-11-21 | Yanjun Wang | Biomarker for immune checkpoint blockade therapy in nsclc |
| WO2025174933A1 (en) | 2024-02-14 | 2025-08-21 | Genentech, Inc. | Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DE69428764T2 (de) | 1993-12-24 | 2002-06-20 | Merck Patent Gmbh | Immunokonjugate |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| WO1996003397A1 (en) | 1994-07-21 | 1996-02-08 | Akzo Nobel N.V. | Cyclic ketone peroxide formulations |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| SI9620103A (sl) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1998050038A1 (en) | 1997-05-06 | 1998-11-12 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| BR9814116A (pt) | 1997-11-06 | 2000-10-03 | American Cyanamid Co | Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico |
| EA003786B1 (ru) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
| CA2769822C (en) * | 2009-08-13 | 2019-02-19 | The Johns Hopkins University | Methods of modulating immune function |
| GB0917457D0 (en) * | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
| JP5892794B2 (ja) * | 2009-10-02 | 2016-03-23 | 学校法人 久留米大学 | 癌患者に対する免疫療法の治療効果および／または免疫療法後の予後の予測方法、ならびに該方法に用いる遺伝子セットおよびキット |
| US9404926B2 (en) * | 2010-01-29 | 2016-08-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Immune gene signatures in cancer |
| US8802438B2 (en) | 2010-04-16 | 2014-08-12 | Children's Medical Center Corporation | Compositions, kits, and methods for making induced pluripotent stem cells using synthetic modified RNAs |
| US20120258878A1 (en) * | 2010-08-04 | 2012-10-11 | Med Biogene Inc. | Prognostic gene signatures for non-small cell lung cancer |
| MX368257B (es) * | 2011-08-01 | 2019-09-26 | Genentech Inc | Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer. |
| EP2615181A1 (en) * | 2012-01-10 | 2013-07-17 | Universite Joseph Fourier - Grenoble 1 | Cyclon expression for the identification and control of cancer cells |
| HK1203971A1 (en) * | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| EP2880180B1 (en) * | 2012-08-06 | 2018-10-03 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and kits for screening patients with a cancer |
| WO2014078468A2 (en) * | 2012-11-15 | 2014-05-22 | Bristol-Myers Squibb Company | Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent |
-
2015
- 2015-12-29 JP JP2017534648A patent/JP2018503373A/ja active Pending
- 2015-12-29 WO PCT/US2015/067878 patent/WO2016109546A2/en not_active Ceased
- 2015-12-29 EP EP15832855.9A patent/EP3240908A2/en active Pending
- 2015-12-29 CN CN201580070110.8A patent/CN107208138A/zh active Pending
-
2017
- 2017-05-31 US US15/609,473 patent/US11236394B2/en active Active
-
2021
- 2021-03-01 JP JP2021031306A patent/JP7325463B2/ja active Active
- 2021-12-17 US US17/554,966 patent/US12385098B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503373A5 (enExample) | ||
| Fridman et al. | Tertiary lymphoid structures and B cells: An intratumoral immunity cycle | |
| Gavrielatou et al. | Biomarkers for immunotherapy response in head and neck cancer | |
| JP7430136B2 (ja) | 疲弊したｔ細胞に関連する疾患を治療するための方法および組成物 | |
| RU2017119231A (ru) | Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40 | |
| JP2017536842A5 (enExample) | ||
| JP2026027390A (ja) | 腫瘍微小環境の特性を使用するキメラ受容体ｔ細胞治療 | |
| CN106973568B (zh) | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 | |
| US20220332823A1 (en) | Methods of treating cancer | |
| EP4104187A1 (en) | Method of predicting response to chimeric antigen receptor therapy | |
| WO2016196389A1 (en) | Treatment of renal cell carcinoma | |
| JP2023508947A (ja) | 循環腫瘍ｄｎａの分析を介した分子疾患評価のための方法およびシステム | |
| WO2019036724A2 (en) | CELLULAR THERAPIES TARGETING MOLECULAR MEDIATORS ASSOCIATED WITH DISEASE, FIBROUS, INFLAMMATORY, AND AUTOIMMUNE CONDITIONS | |
| CN112805378A (zh) | 用于评估整合核酸的方法 | |
| CN113710274A (zh) | 用于预测癌症免疫疗法中的长期存活的方法及组合物 | |
| Watson et al. | Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift? | |
| Wang et al. | Cancer immunology: immune escape of tumors—expression and regulation of HLA class I molecules and its role in immunotherapies | |
| KR101968452B1 (ko) | 면역요법 효능의 임상적 상관물 | |
| KR20230124912A (ko) | 키메라 수용체 및 이의 사용 방법 | |
| Guo et al. | Transcriptome deconvolution reveals absence of cancer cell expression signature in immune checkpoint blockade response | |
| Wagner et al. | Conserved programs and specificities of T cells targeting hematological malignancies | |
| Sivakumar et al. | Single-cell immune multi-omics and repertoire analyses in pancreatic ductal adenocarcinoma reveal differential immunosuppressive mechanisms within different tumour microenvironments | |
| Le et al. | TIGIT as a therapeutic target of HPV-positive head and neck squamous cell carcinomas | |
| Mestrallet | Immune response and resistance of clear cell renal cell carcinoma patients following immune checkpoint blockade | |
| Ren et al. | Single-cell Profiling of Immune cells After Neoadjuvant Pembrolizumab and Chemotherapy in ⅢA non-small cell lung cancer (NSCLC) |